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Traumatic brain injury (TBI) is a major cause of death and disability in young people. No effective therapy is available to ameliorate
its damaging effects. Our aim was to investigate the optimal therapeutic time window of edaravone, a free radical scavenger which
is currently used in Japan. We also determined the temporal profile of reactive oxygen species (ROS) production, oxidative stress,
and neuronal death. Male C57Bl/6 mice were subjected to a controlled cortical impact (CCI). Edaravone (3.0mg/kg), or vehicle,
was administered intravenously at 0, 3, or 6 hours following CCI.The production of superoxide radicals (𝑂
2
∙−) as a marker of ROS,
of nitrotyrosine (NT) as an indicator of oxidative stress, and neuronal death were measured for 24 hours following CCI. Superoxide
radical production was clearly evident 3 hours after CCI, with oxidative stress and neuronal cell death becoming apparent after 6
hours. Edaravone administration after CCI resulted in a significant reduction in the injury volume and oxidative stress, particularly
at the 3-hour time point. Moreover, the greatest decrease in 𝑂
2
∙− levels was observed when edaravone was administered 3 hours
following CCI. These findings suggest that edaravone could prove clinically useful to ameliorate the devastating effects of TBI.
1. Introduction
In spite of the fact that traumatic brain injury (TBI) is a
major cause of death and disability, particularly in young
people, and given the huge socioeconomic costs of caring
for affected persons, there is still no adequate treatment
available to ameliorate its damaging effects [1, 2]. The overall
incidence of TBI in the United States is estimated to be 540
cases per 100,000 persons and the prevalence of long-term
disability is estimated to be between 3.2 and 5.3 million. In
2000, the economic impact of TBI in the United States was
estimated to be $9.2 billion in lifetimemedical costs and $51.2
billion in lost productivity. Falls and motor vehicle accidents
are the leading causes of TBI, with most cases transferred
immediately to an emergency department [3]. Given that
moderate and severe TBIs are associated with neurologic and
functional impairments [4], further intensive care following
initial treatment and diagnostic assessment are also usually
required.
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a
derivative of antipyrin and was approved as free radical
scavenger for the treatment of acute cerebral infarction in
Japan [5]. Edaravone was first reported to strongly scavenge
hydroxyl radicals (OH−) produced by the Fenton reaction in
vitro and to decrease lipid and L-tyrosine oxidation [6]. The
effects of edaravone have been studied in relation to brain
ischemia in animals and humans, and decreased brain edema,
infarction, endothelial damage, and oxidative damage have
been reported [6–11]. Edaravone has also been used in other
neural injury models such as spinal cord injury [12], TBI
[8, 13, 14], and brain hemorrhage [15] andwas found to reduce
lesion size and oxidative stress levels. We have previously
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reported that intravenous edaravone (3.0mg/kg) treatment
immediately after cortical impact suppressed traumatic neu-
ral damage in rodents [13] and decreased hydroperoxide
(ROO∙) and alkoxyl (RO∙) radical formation in both rodents
and patients with TBI [13, 16]. Edaravone treatment at 2
hours and again at 12 hours also decreased neuronal loss
in a dose-dependent fashion (0.75, 1.5, or 3mg/kg) in the
CA3 layer of the hippocampus after TBI [8], while at 3mg/kg
i.v it suppressed apoptotic neuronal cell death and oxidative
damage after TBI [14]. In spite of these positive outcomes, the
therapeutic time window of edaravone on TBI has not been
examined in detail.
It has been suggested that reactive oxygen species (ROS)
generation is activated in the lesion area after TBI, leading to
the initial production of superoxide (O2
∙−) and nitric oxide
(∙NO) radicals.These ROS then react andmetabolize to form
stronger oxidants in the form of peroxynitrite (ONOO−),
hydroxyl (∙OH), carbonate (CO3
∙−), and nitrogen dioxide
(∙NO
2
) radicals [17, 18], which in turn react with proteins,
lipids, sugars, and nucleotides and impair the normal phys-
iological function of cells. Although it is considered that O2
∙−
does not have strong oxidative potential and that edaravone
does not scavenge O2
∙− in vitro [6], we previously reported
thatmice deficient inGp91phox (NOX2), a subunit of NADPH
oxidase and a generator of O2
∙−, exhibited reduced lesion size
and oxidative stress following TBI [19]. Moreover, knockout
mice lacking interleukin-1, a proinflammatory cytokine, were
less susceptible to neuronal cell death than their wild-type
littermates and displayed less inducible nitric oxide synthase
gene expression and reduced O2
∙− and ONOO− production
during ischemia [20, 21].
In the present study, we investigated the therapeutic time
window of edaravone on TBI and oxidative metabolite gen-
eration in mice following a controlled cortical impact (CCI).
We also evaluated the temporal profile of ROS production,
oxidative stress, and neuronal cell death in order to estimate
the relationship between the effect of edaravone on brain
damage and the sequence of events leading to ROS generation
following CCI.
2. Materials and Methods
2.1. Animals and CCI Model. All experimental procedures
involving animals were approved by the Institutional Animal
Care and Use Committee of Showa University (#00158).
Young adult male C57/BL6 mice (8–12 weeks of age, 20–26 g
per body weight) were anesthetized with 2% sevoflurane in
N
2
O/O
2
(70%/30%) and positioned in a computer-guided
stereotaxic system (Leica Angle Two, Leica Microsystems,
Wetzlar, Germany) incorporating an electromagnetic CCI
device (Benchmarked Stereotaxic Impactor, Leica Microsys-
tems). Following a midline scalp incision, a 4mm2 opening
was made in the skull 3mm lateral and 2mm caudal of
bregma, thereby exposing the right parietotemporal cortex. A
CCI was carried out at a depth of 1.0mm from the duramater
at a stroke velocity of 3.7m/second, using an impact device
with a rounded tip of approximately 1.2mm in diameter
(Figures 1(a) and 1(b)) [22].
After removing hemorrhaged blood resulting from the
impact, the skull was covered with 4mm diameter artificial
dura (GORE Preclude, W. L. Gore & Associates, Newark, NY,
USA) and a 5mm diameter artificial bone plate made from
dental cement (GC Fuji I, GC Corporation, Tokyo, Japan).
The core body temperature of the mice was maintained at
37∘C during the surgery.
2.2. Experimental Design. We performed 3 experiments as
given in the following.
Experiment 1. The animals were divided into 4 experimental
groups to determine the possible therapeutic time window
of edaravone (3.0mg/kg, 𝑛 = 10 for each group). Group 1
(Ed 0 h): edaravone was administered immediately (0 hour)
after the CCI. Group 2 (Ed 3 h): edaravone was administered
3 hours following CCI. Group 3 (Ed 6 h): edaravone was
administered 6 hours following CCI. Group 4, vehicle (Vh):
this served as the control group in which normal saline was
given immediately (0 hour) following CCI (𝑛 = 9). All
animals were sacrificed 24 hours following CCI (Figure 1(d)).
Experiment 2. Mice (𝑛 = 3 in each group) were divided into 4
groups. They were sacrificed group 1: immediately (0), group
2: 3 hours, group 3: 6 hours, and group 4: 24 hours after CCI
to investigate the temporal profiles of ROS, oxidative stress,
and neuronal death in the brain (Figure 1(e)).
Experiment 3. Three groups were set (𝑛 = 3 in each group)
to investigate the effect of edaravone treatment to ROS
(Figure 1(f)). Group 1 (Ed 0 h): edaravone was administered
immediately (0 hour) after the CCI and in situ detection of
O2
∙− was performed 4 hours after CCI. Group 2 (Ed 3 h):
edaravone was administered 3 hours following CCI and in
situ detection of O2∙− was performed 4 hours following CCI.
Group 3 (Vh 3 h): vehicle was administered 3 hours after CCI
and in situ detection of O
2
∙− was also performed 4 hours
following CCI as the control group.
2.3. Administration of Edaravone. Edaravone, a free radical
scavenger, was a gift fromMitsubishi Tanabe Pharma (Osaka,
Japan). Animals were placed in the supine position and
anesthetized with sevoflurane administered by inhalation
through a facemask.The skin over the left clavicle was incised
to expose the left jugular vein. Edaravone dissolved in saline
was slowly administered at a dosage of 3.0mg/kg bodyweight
(100–150𝜇L volume) into this vein.
2.4. Tissue Preparation. Under sodiumpentobarbital (50mg/
kg, i.p.) anesthesia, the animals were transcardially perfused
with 0.9% NaCl followed by 2% paraformaldehyde (PFA) in
50mM phosphate buffer (pH 7.2). The brain and skull were
then removed intact and postfixed in 2% PFA overnight,
after which the skull was carefully removed, and the brain
was immersed in 20% sucrose for 2 days for cytoprotection.
The brain was next frozen in liquid nitrogen-chilled 2-
methylbutane and coronally cryosectioned at a thickness
of 50𝜇m from bregma to approximately 3.9mm caudal
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Figure 1: Establishment of TBI model and experimental protocol. (a) Brain images following TBI. The contusion was conducted over the
right parietotemporal cortex 2.0mm caudal of bregma and 3.0mm lateral of the midline. (b) High power images of the CCI device showing a
rounded tip of approximately 1.2mm in diameter. (c) Coronal cryosections (thickness 50 𝜇m) from bregma to approximately 3.9mm caudal
of bregma encompassing the injury regionwere used to determine the injury area.The core-injury area was defined as the direct impact region
1.2mm to 2.4mm caudal of bregma. The peri-injury area was defined as being <1.2mm and >2.4mm caudal of bregma. (d) The free radical
scavenger edaravone was injected intravenously into the jugular vein following CCI. To determine the possible therapeutic time window,
edaravone (3.0mg/kg, 𝑛 = 10 for each time point) was administered either immediately (0) or 3 or 6 hours following CCI. As a vehicle-
treated control group, saline was administered immediately (0 hour) following CCI (𝑛 = 9). (e) Temporal profiles of ROS, oxidative stress,
and neuronal death in the brain following CCI were determined immediately (0) and at 3, 6 and 24 hours after CCI (𝑛 = 3). (f) Edaravone
treatment to ROS was investigated. Edaravone was administered to group 1: immediately (0 hour) or group 2: 3 hours after the CCI and in situ
detection of O2∙− were performed 4 hours post-CCI. As the control, Group 3: vehicle was administered 3 hours post-CCI and in situ detection
of O2∙− was also performed 4 hours following CCI.
of bregma, thus ensuring coverage of the injured region
(Figure 1(c)). The sections were then immediately immersed
in PBS containing 0.1% Tween 20 (PBST) for subsequent
histological assessment.
2.5. Fluoro-Jade B and Toluidine Blue Staining. Fluoro-Jade
B (FJB) staining was used to detect degenerating neurons
as previously reported, with only minor modifications [23,
24]. A series of sections was collected at 600 𝜇m intervals
from 0 to 3.6mm caudal of bregma (7 sections per mouse)
and mounted on poly-L-lysine-coated glass slides. After air
drying, the slides were incubatedwith freshly prepared 0.06%
potassium permanganate for 15min and rinsed with distilled
water. The sections were then immersed in 0.0005% FJB
(Millipore, Billerica, MA, USA) in a dark room for 30min,
after which they were completely air-dried before being
immersed in xylene and enclosed in malinol (Muto Pure
Chemicals, Tokyo Japan). A second series of adjacent sections
was stained with toluidine blue (TB) [25]. The sections
were observed with a fluorescence microscope (Biozero 8100,
Keyence, Osaka, Japan).
2.6. Measurement of Lesion Volume. FJB- and TB-stained
sections were used to semiquantify the injury area based
on sections that displayed FJB labeling or little or no TB
staining. Some sections, particularly those near the injury
core, lacked part of the neocortex due to severe tissue damage;
this area was also included in our calculations of lesion
volume. The outlines of the affected regions were traced, and
the areas were calculated using NIH Image software. The
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injury volume was then determined by summing these areas.
This was performed by an investigator whowas blinded to the
experimental groups.
We further defined core- and peri-injury areas. Given that
the diameter of the impact tip was around 1.2mm, we defined
the core-injury area as encompassing the region 1.2mm to
2.4mmcaudal of bregma, with the peri-injury area surround-
ing this (Figure 1(c)).
2.7. Immunostaining of Nitrotyrosine (NT). Another series
of sections at 600𝜇m intervals (6 sections per animal)
was used to label for nitrotyrosine (NT), a peroxynitrite
(ONOO−) oxidative metabolite, by free-floating immunohis-
tochemistry. After immersion in 0.3% H
2
O
2
, the sections
were incubated in 5% normal horse serum and immersed
overnight with a polyclonal affinity-purified rabbit anti-NT
antibody (1 : 1000, Upstate Biotechnology, Lake Placid, NY,
USA). The sections were then incubated with biotinylated
goat anti-rabbit IgG (1 : 200, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), followed by an avidin-biotin complex
solution (Vector, Burlingame, CA, USA) using diaminoben-
zidine (Vector) as a chromogen. The area of dark brown
NT-immunopositive staining as well as that of the severely
damaged core-injury region as determined using NIH Image
software and the injury volume calculated by summing these
areas.
To determine the identity of the NT-positive cells, we
colabeled for various cell markers. After blocking, the sec-
tions were coincubated with anti-NT antibody and either
monoclonal mouse anti-NeuN antibody (1 : 2000, a neuronal
marker, Millipore) or monoclonal mouse anti-glial fibril-
lary acidic protein (GFAP) antibody (1 : 2000, an astroglial
marker, Sigma, St. Louis, MO, USA), followed by the sec-
ondary antibodies Alexa 488-conjugated goat anti-rabbit
IgG antibody (1 : 400) and Alexa 546-conjugated goat anti-
mouse IgG antibody (1 : 800, Molecular Probes, Eugene,
OR). Nuclei were stainedwith 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI, 1 : 10,000; Roche, Mannheim, Ger-
many).
2.8. In Situ Detection of O2∙−. Hydroethidium (HEt) rapidly
penetrates into the brain parenchyma, reacts with O2
∙−,
and generates ethidium (Et) which can be detected at an
emission wavelength of 510–550 nm [26, 27]. Mice were
anesthetized with 2% sevoflurane in N
2
O/O
2
(70%/30%) and
were administered 1.0mg/mL HEt solution (in 0.9% NaCl
containing 1% DMSO) into the left jugular vein. Fifteen
minutes after HEt infusion, the animals were perfuse-fixed
and their brains frozen and sectioned. To identify the Et-
positive cells, some sections were also stained with primary
antibody for NeuN or GFAP. All sections were nuclear-
stained with DAPI. Fluorescence was detected using an Axio
Imager optical sectioning microscope with an ApoTome
slider module.
2.9. Statistical Analysis. Data were expressed asmean ± SEM.
Statistical comparisons were made by Student’s t-test for two
groups and by one-way ANOVA followed by Tukey-Kramer
tests for multiple group comparisons. A value of 𝑃 < 0.05
was considered to indicate statistical significance.
3. Results
3.1. Edaravone Has a Therapeutic Time Window of 6 Hours
for the Treatment of TBI. We commenced by investigating
the effect of edaravone and the optimal therapeutic time
window for its administration in our experimental TBI
model. Animals were administered either vehicle (0 hours;
𝑛 = 9) or 3.0mg/kg edaravone (0, 3, or 6 hours after CCI)
(𝑛 = 10) (Figure 1(d)) and the efficacy of this treatment
was evaluated at 24 hours based on FJB (Figure 2) and TB
(Figure 3) staining.
One vehicle-treated mouse died during the experiment.
The total injury volume calculated from FJB staining was
significantly reduced in edaravone-treated animals (0 h: 4.83
± 0.32mm3, 𝑃 < 0.01; 3 h: 3.13 ± 0.43mm3, 𝑃 < 0.001;
6 h: 4.31 ± 0.50mm3, 𝑃 < 0.001) compared with that in the
vehicle-treated cohort (0 h: 6.38 ± 0.34mm3). Interestingly,
the total injury volume in mice treated with edaravone at
3 hours was significantly less than that which occurred in
those treated at 0 hours (𝑃 < 0.05), with the former animals
also displaying the strongest neuroprotection observed across
all groups. No significant differences in injury volumes were
recorded between the 0- and 6-hour or the 3- and 6-hour
treatment groups (Figure 2).
To confirm these results, we determined the injury
volume based on TB staining and obtained similar results
(Figure 3). The total injury volume detected by TB staining
was significantly reduced in the edaravone-treated groups
(0 h: 4.78 ± 0.40mm3, 𝑃 < 0.05; 3 h: 3.09 ± 0.39mm3, 𝑃 <
0.001; 6 h: 3.75 ± 0.51mm3, 𝑃 < 0.01) compared with the
vehicle-treated controls (0 h: 6.14 ± 0.42mm3), with the best
result again being obtained for the 3-hour treatment group
compared with the 0-hour group (𝑃 < 0.05).
To estimate which region of the affected tissue edaravone
rescued from cell death, we also analyzed the volume of
the core- and peri-injury areas separately using FJB staining
(Figure 2(d)). The animals treated with edaravone at 0
hours had a significantly lower peri-injury volume compared
with controls treated with vehicle at the same time point
(2.08 ± 0.17mm3 versus 3.09 ± 0.21mm3, 𝑃 < 0.01), but
no significant difference was observed for the core-injury
volume (2.75± 0.18mm3 versus 3.29± 0.19mm3). In contrast,
edaravone treatment at both 3 and 6 hours significantly
reduced the TBI-induced volumes in both the core- (3 h: 1.64
± 0.31mm3, P < 0.001; 6 h: 2.06 ± 0.16mm3, 𝑃 < 0.05) and
peri- (3 h: 1.49 ± 0.21mm3, P < 0.001; 6 h: 2.11 ± 0.36mm3,
𝑃 < 0.001) injury sites. To be more specific concerning
the core injury area, edaravone treatment at both 3 and 6
hours rescued the frontal region to a greater extent than
that seen for the 0-hour treatment (Figure 2(b)). Notably,
the core-injury volume following edaravone administration
at 3 hours was significantly less than that measured in
response to edaravone treatment at 0 hours. The results
for TB staining were similar to those for FJB staining
(Figure 3).
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Figure 2: Effect of edaravone on TBI following CCI. (a) Representative core- (upper) and peri-injury (lower) images of FJB staining at 24
hours following CCI. Edaravone was injected 0, 3, or 6 hours following CCI; vehicle treatment occurred at 0 hours. The inset shows a higher
power view of the boxed region in the main image. (b) The TBI area was semiquantified for each experimental group. Edaravone (𝑛 = 10)
treatment at 3 and 6 hours led to a significant decrease in the core-injury area compared with the vehicle-treated control (𝑛 = 9). The injury
volume was calculated by integration of the TBI areas and expressed as total (c) or core- and peri-injury (d) volumes. Data are expressed as
mean ± SEM. Asterisk (∗) indicates a significant difference between groups based on Tukey-Kramer tests (𝑃 values are described in the text).
3.2. Edaravone Treatment Suppresses Oxidative Stress follow-
ing TBI. Theprevious results revealed that edaravone reduces
the area affected by TBI and that it can exert a therapeutic
effect when administered up to 6 hours following injury.
As previous studies have reported that edaravone acts as a
radical scavenger and reduces oxidative stress in a number of
diseases [28–30], we therefore next investigated whether the
effect of edaravone in our model was due to the suppression
of oxidative stress. To assess this, we determined the NT-
positive volume 24 hours after CCI in animals treated with
either vehicle (𝑛 = 9) at 0 hours or edaravone (𝑛 = 10) at 0,
3, or 6 hours (Figure 1(d)). The total NT-positive volumes for
the edaravone-treated groups at 0 hours (3.91 ± 0.15mm3, P <
0.001), 3 hours (2.28 ± 0.30mm3, P < 0.001), and 6 hours (3.15
± 0.45mm3, P < 0.001) were significantly less than those of
the vehicle-treated control mice (6.14 ± 0.38mm3) (Figure 4).
There was also a marked difference between the 0- and 3-
hour edaravone treatment groups (3.91 ± 0.15mm3 versus
2.28 ± 0.30mm3, P < 0.001). Similar results were obtained
for the core- and peri-injury volumes of the animals treated
with edaravone at 3 hours (core: 1.33 ± 0.16mm3, P < 0.001;
peri: 0.95 ± 0.38mm3, P < 0.001) and 6 hours (core: 1.83 ±
0.23mm3, P < 0.01; peri: 1.32 ± 0.22mm3, P < 0.01) compared
with the vehicle-treated controls (core: 3.29 ± 0.28mm3;
peri: 2.85 ± 0.15mm3). However, 0-hour edaravone treatment
only produced a significant (P < 0.05) decrease in the NT-
positive peri-injury volume (core: 2.81 ± 0.28mm3; peri: 1.94
± 0.22mm3).Moreover, the animals treatedwith edaravone at
3 hours showed significantly greater neuroprotection at both
the core- and peri-injury sites versus the 0-hour treatment
group (Figure 4).
3.3. Neurodegeneration in the Core Injury Area Occurs at 6
Hours following CCI and Spreads to Peri-Injury Area with
Time. We next determined the time course (Figure 1(e)) of
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Figure 3: Effect of edaravone on TBI after CCI based on TB staining. (a) Representative core- (upper) and peri-injury (lower) images of TB
staining 24 hours after CCI. The region with little or no staining was defined as the injury area. Edaravone (𝑛 = 10) was injected at 0, 3, or
6 hours and vehicle (𝑛 = 9) at 0 hours after CCI. The total (b) or core- and peri-injury (c) areas were semiquantified in each experimental
group. Data are expressed as mean ± SEM. Asterisk (∗) indicates a significant difference between the groups based on Tukey-Kramer tests.
neurodegeneration following CCI (𝑛 = 3 for each time
point). Only a few FJB-positive cells were present in the core-
injury area 3 hours after CCI. By 6 hours, however, diffusely
scattered FJB-positive cells were observed not only in the core
injury area but also in the peri-injury area. By 24 hours, both
the number of FJB-positive cells and the size of the affected
area had increased even further (Figure 5).The injury volume
was significantly greater at 6 (2.49 ± 0.30mm3, P < 0.01) and
24 hours (6.38 ± 0.34mm3, P < 0.01) compared with 0 (𝑛 = 3,
0.10 ± 0.03mm3) and 3 (0.19 ± 0.05mm3) hours (Figure 5(c)).
3.4. Oxidative Metabolites Increase 6 Hours after CCI in
Neurons. We subsequently investigated the temporal profile
(Figure 1(e)) of oxidative stress by using NT immunos-
taining after CCI (𝑛 = 3 for each time point). Minimal
immunoreactivity was observed immediately after CCI (0 h).
However, dark brown NT staining began to appear from 6
hours following CCI in the neocortex around the epicenter
of the impact site. By 24 hours, the NT-positive area had
expanded and some of the tissue at the impact site had been
lost (Figure 6(a)). The volume of the NT-positive region
increased significantly in a time-dependent manner after
CCI, accounting for 0.18 ± 0.03mm3, 0.38 ± 0.10mm3, and
2.07± 0.63mm3 (𝑃 < 0.05 versus 0 hour) and 6.14± 0.38mm3
(𝑃 < 0.01 versus 0 hour) at 0, 3, 6, and 24 hours after CCI,
respectively (Figure 6(b)).
Colabeling with cell markers at the core-injury site
indicated that the oxidative stress was occurring mainly in
neurons (Figure 6(c)).
3.5. ROS Increases in Neurons 3 Hours after CCI. We next
determined the time course (Figure 1(e)) of ROS generation
based on the in situ detection of O2∙− using HEt at 0, 3, 6,
and 24 hours following CCI (𝑛 = 3 for each time point). A
low Et signal was initially observed in the core-impact region.
However, by 3 hours following CCI, this signal had increased
markedly and continued to rise slightly up until the 24-hour
time point (Figure 7(a)). Colabeling for Et and various cell
markers revealed that the affected cells were mainly NeuN-
positive neurons (Figure 7(b)).
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Figure 4: Effect of edaravone on oxidative stress followingCCI. (a) Representative core- (upper) and peri-injury (lower) images ofNT staining
at 24 hours following CCI. Edaravone (𝑛 = 10) was injected at 0, 3, or 6 hours following CCI; vehicle (𝑛 = 9) treatment occurred at 0 hours.
The inset shows a higher power view of the boxed region in the main image. The injury volume was calculated by integration of the TBI
areas (based on seven 50 𝜇m coronal sections at 500𝜇m intervals) and expressed as total (b) or core- and peri-injury (c) volumes. Data are
expressed as mean ± SEM. Asterisk (∗) indicates a significant difference between groups based on Tukey-Kramer tests (𝑃 values are described
in the text).
3.6. Edaravone Suppresses the ROS Production Cycle following
CCI. Finally, we also investigated the effect of edaravone
treatment 3 hours following CCI on O2
∙− generation at
the core-injury site using HEt injection. Mice (𝑛 = 3
in each group) were administered edaravone 0 or 3 hours
following CCI or vehicle 3 hours following CCI, with the
Et signal evaluated 4 hours after injury as a measure of
O2
∙− generation. As illustrated in Figure 7(c), vehicle-treated
brains showed a large number of affected cells and a strong Et
signal intensity. Fewer cells were affected following edaravone
treatment at 0 hours, but the intensity of the Et signal became
stronger thereafter.However, the 3-hour treatment resulted in
only a few affected cells and a very weak Et signal, suggesting
that edaravone administered at this time point suppressed
the ROS and oxidative stress cycle and provided a greater
neuroprotective effect.
4. Discussion
Edaravone is a free radical scavenger approved in Japan for
the treatment of stroke. It could be a suitable candidate
for treating TBI as well, given the results of several rodent
studies showing that this drug is able to decrease neuronal cell
death. However, the therapeutic time window of edaravone
on TBI has not been examined in detail. In the present
study, we have demonstrated that the intravenous injection
of edaravone (3mg/kg) decreased TBI and reduced oxidative
stress when administered after a delay of up to 6 hours
following CCI. We also determined the temporal profiles of
ROS production, oxidative stress, and neuronal cell death in
order to understand the relationship between brain damage
and the sequence of events underlying ROS generation
following CCI.
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Figure 5: Detection of neuronal cell death by FJB labeling after CCI. (a) Neuronal cell death, as indicated by FJB labeling, increases in a
time-dependent manner after CCI (𝑛 = 3 at each time point). No FJB-positive cells were observed at 0 (also see inset) and 3 hours after CCI;
however, by 6 and 24 hours (also see inset), FJB labeling and an increase in the area of cortical disruption produced by the contusion were
observed. (b) Seven 50𝜇m coronal sections at 500𝜇m intervals were used to semiquantify the area of FJB immunoreactivity, together with
the area of cortical disruption produced by the TBI. This analysis revealed a marked increase in the affected area at 6 and 24 hours. Data
are expressed as mean ± SEM (𝑛 = 3). (c) A significant increase in the TBI volume was observed 6 and 24 hours following CCI. Data are
expressed as mean ± SEM (𝑛 = 3). Asterisk (∗) indicates a significant difference between groups based on Tukey-Kramer tests (𝑃 values are
described in the text).
We previously reported that the intravenous adminis-
tration of edaravone (3mg/kg) immediately after TBI sup-
pressed cortical damage [13]. Another study also demon-
strated that edaravone injected 2 and 12 hours after TBI
decreased neuronal cell loss in the CA3 layer of the hip-
pocampus in a dose-dependent fashion (0.75, 1.5, or 3mg/kg)
[8]. In the present study, we examined the therapeutic
time window of intravenously injected edaravone (3mg/kg)
on TBI and showed that edaravone administered for up
to 6 hours at least after CCI suppressed the lesion size.
Comparisons of lesion sizes following edaravone treatment
at 0, 3, and 6 hours after CCI demonstrated that edaravone
treatment at 3 hours provided the greatest neuroprotective
effect compared with the other treatment groups and that
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Figure 6: Detection of oxidative stress by NT labeling following CCI. (a) Very few NT-immunopositive cells were observed at 0 (also see
inset) and 3 hours following CCI; however by 6 and 24 hours (also see inset) this number, and the area of cortical disruption produced by the
contusion, had increased markedly. (b) Semiquantification of the NT-positive volume revealed a significant increase at 6 and 24 hours after
CCI. Data are expressed as mean ± SD (𝑛 = 3). Asterisk (∗) indicates a significant difference between groups based on Tukey-Kramer tests
(𝑃 values are described in the text). (c) Multiple immunofluorescence staining of NT and cell markers. The NT-positive staining overlapped
with that of the neuronal marker, NeuN (green, upper panel), but not with the astroglial marker, GFAP (green, lower panel).The sections were
also counterstained with the nuclear dye DAPI (blue).
a significant difference was observed compared with treat-
ment at the 0-hour time point. To estimate the extent of
the neuroprotective effect, we further compared the lesion
size by measuring both core- and peri-injury areas. Edar-
avone treatment 6 hours after CCI decreased the lesion
size significantly both in the peri- and core-injury sites
compared with control, but the area was slightly larger than
that seen in mice treated with edaravone 3 hours after CCI.
Although mice treated with edaravone at the 0-hour time
point showed a significantly decreased lesion size in the
peri-injury site compared with vehicle-treated animals, no
statistically significant differences with respect to the core-
injury site size were seen. Furthermore, the size of the core-
injury site in the 0 hour edaravone treatment group was
significantly greater than that measured in mice treated 3
hours after CCI. In particular, the lesion size in the frontal
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Figure 7: In situ detection of ROS as O2∙− using Het. (a) NoO2∙− (Et) signals (red) were detected in control animals. Inmice subjected to TBI,
a low level of O2
∙− was observed immediately after CCI. By 3 hours this level had increasedmarkedly, remaining high 6 and 24 hours after CCI.
(b) Multiple immunofluorescence staining of O2
∙− and cell markers. O2
∙− (Et) signals (red) strongly colocalized with the neuronal marker
NeuN (green, upper panel) and to lesser extent with the astroglial marker GFAP (green, lower panel), with nuclei labelled by DAPI (blue). (c)
The effect of edaravone treatment on O2
∙− production after CCI (𝑛 = 3 in each group) is shown. As a control, vehicle was administered 3
hours post-CCI (vehicle 3 h). Edaravone was administered at 0 hours (edaravone 0 h) or 3 hours (edaravone 3 h) after CCI. The production
of O2
∙− was evaluated based on the in situ detection of the Et signal (red) in the core-injury area 4 hours after CCI. Nuclei (blue) were labeled
with DAPI.
area was significantly different between these two groups.
Observations made with respect to NT immunostaining as
an indicator of oxidative stress also demonstrated a similar
tendency to that seen with lesion size.
We subsequently examined the temporal profiles of ROS
production, oxidative stress, and neuronal cell death in
order to understand the relationship between brain damage
and the sequence of events giving rise to ROS generation
following CCI. Superoxide detected by HEt was used for
the determination of ROS levels because O2
∙− is initially
increased after injury [26], while the oxidative metabolites
ONOO− and ∙OH also contribute to increasing oxidative
stress and damage in tissue [11]. The O2
∙− signal was initially
observed 3 hours following CCI and increased with time up
to 24 hours. The oxidative stress detected by NT, which is
a metabolite of L-tyrosine oxidation by ONOO− [31], was
observed at 6 hours following CCI in the core-injury region
and increased for up to 24 hours with extension to the peri-
injury area. This was reflected in the rise in O2
∙− production
and the concomitant increase in neuronal cell death detected
by FJB staining, suggesting that excessive O2
∙− production
after CCImight result in the induction of oxidative stress and
neurodegeneration in the brain.
From the results of the temporal profiles of ROS pro-
duction, oxidative stress, and neuronal cell death, the effects
of treatment with edaravone were consistent with the time
points which fall before, during, and after the production of
ROS, respectively.While a precise explanation for this cannot
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be given, we suggest that it could have something to do with
the half-life of edaravone, which is reported to be approx-
imately one hour [29]. Therefore, the animals treated with
edaravone immediately after (0 hour) CCI might actually
have had a decreased effective concentration of this drug at
the time of maximum ROS production. By 6 hours following
CCI, a weaker neuroprotective effect was observed due to the
fact that significant oxidative damage and neuronal cell death
had already occurred. Nonetheless, treatment at this time
point still had a therapeutic effect given that the level of ROS
continued to increase for 24 hours. These results suggest that
there might be an optimal time for treatment with edaravone
to suppress the degree of injury. An experimental study in
whichmice were exposed to hypobaric conditions for 3 hours
after TBI supports our present results; these animals showed
exacerbated secondary traumatic injury severity because
of a greatly heightened inflammatory response due to the
hypobaric condition [32]. We recently found that edaravone
improved cerebral blood flow (CBF) after TBI [33]. In this
way, CBF in control animals in that study was significantly
reduced, probably as a consequence of vasospasm, in the
ipsilateral hemisphere of the brain 3 to 6 hours after CCI [33].
Treatment with edaravone significantly ameliorated the CBF.
Other studies have reported that edaravone improves blood
circulation in the heart [34] and lung [27], suggesting that
edaravone treatmentmay suppress traumatic ischemic injury,
as observed in the present study, by ameliorating circulation.
This finding is important given that most TBIs are
associated with falls and motor vehicle accidents. There-
fore, in most cases the onset of TBI is clear and patients
are transferred to an emergency department within a few
hours. From a clinical perspective, it is noteworthy that
delayed treatment with edaravone in our study was more
efficacious than administration immediately after the CCI;
the time delay between the onset of ROS production and
neuronal cell death means probably that these cases would
fall within a therapeutic time window for the treatment of
TBI. At the present time, edaravone (60mg/day injected
intravenously in 2 divided doses) is used in Japan for the
treatment of stroke. Therefore, the dosage of edaravone in
our study was approximately triple compared with clinical
use. Further study is required to determine the minimum
dosage of edaravone necessary to suppress ROS production
and lesion size in this animal model and for this finding
to be translated to the clinical setting whereby edaravone
is used to suppress the lesion size in clinical cases of
TBI.
Althoughmany studies have reported that oxidative stress
contributes to TBI, very few have linked this directly to
ROS production in the brain. We have previously reported
that both patients suffering a neurological emergency and
animals subjected to TBI display increased blood alkoxy-
radical levels as detected by an electron spin resonance (ESR)
spin trapping method [13, 35]. Based on the rapid elevation
of intracellular Ca2+ and the impairment of CBF, the source
of the O2
∙− is considered to be primarily the mitochondria
[36]. The intracellular O2
∙− impairs mitochondrial function
and induces neuronal cell death. Extracellular O2
∙− might
be produced by NADPH oxidase in microglia/macrophages
followingCCI [19]. Based onour previous demonstration that
mice deficient in one of the subunits of NADPH oxidase,
Gp91phox, display decreased O2
∙− levels and that inhibition
of Gp91phox by apocynin reduces the severity of TBI in
vivo [19, 36, 37], it appears that this extracellular O2∙−
also contributes to the induction of neuronal cell death in
response to injury. Therefore, both intra- and extracellularly
produced O2
∙−, together with their associated metabolites,
may play important roles in the generation of oxidative stress
following CCI.
Many clinical trials of antioxidant agents or radical scav-
engers have been performed in cases of cerebral infarction,
subarachnoid hemorrhage, and TBI [15, 38, 39]. However,
the only agent which has been granted approval to date is
edaravone [9, 40], even though patients are treated without
concomitant monitoring of ROS or oxidative metabolite
levels. Human TBI presents as a more complex and diverse
condition than animal experimental models. Therefore, care
needs to be exercisedwhen determining the likely therapeutic
time window of edaravone. We suggest that edaravone and
possibly other radical scavengers or antioxidants should be
administered in response to ROS generation, meaning that
the bedside monitoring of ROS could shed more light on the
potential benefit of these agents. Recently, some groups have
reported that Overhauser enhanced MRI, which is a double
resonance technique, creates images of free radical distribu-
tion in small animals by enhancing the water proton signal
intensity by means of the Overhauser effect [41]. Although
not available for bedside monitoring, this technique could
be adapted to directly monitor ROS levels in the brain.
We have also previously reported that one particular ROS,
the alkoxy radical, is increased both in patients suffering a
neuroemergency and in animals subjected to TBI and can
be monitored by ESR [13, 35]. These new techniques could
represent powerful tools for the diagnosis of ROS production
prior to oxidative stress, thereby facilitating more effective
treatment.
5. Conclusion
In the present study, we have demonstrated that edaravone
suppresses neuronal damage in mice subjected to a CCI,
with the greatest effect observed when the drug is given
3 hours after TBI. This time window is consistent with
the increase in ROS produced in the cortex after CCI. We
therefore suggest that edaravone could prove clinically useful
to ameliorate the devastating effects of TBI. To ensure optimal
efficacy, however, it is critical that ROS levels are measured
concomitantly.
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